PCVX - Vaxcyte, Inc.

60.55
-1.440   -2.378%

Share volume: 1,014,448
Last Updated: 04-21-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$61.99
-1.44
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 20%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.89%
1 Month
8.24%
3 Months
12.48%
6 Months
42.44%
1 Year
93.70%
2 Year
-1.70%
Key data
Stock price
$60.55
P/E Ratio 
0.00
DAY RANGE
$60.00 - $62.10
EPS 
-$5.43
52 WEEK RANGE
$28.09 - $65.00
52 WEEK CHANGE
$82.60
MARKET CAP 
6.040 B
YIELD 
N/A
SHARES OUTSTANDING 
143.920 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
-0.12
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,072,664
AVERAGE 30 VOLUME 
$1,225,817
Company detail
CEO: Grant E. Pickering
Region: US
Website: vaxcyte.com
Employees: 160
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials. The company was formerly known as SutroVax, Inc.

Recent news